SNSS Insider Trading Activity and SEC Form 4 Filings
SNSS insider trading summary
No open-market insider purchases or sales of Sunesis Pharmaceuticals Inc (SNSS) have been reported on SEC Form 4 in the past 12 months.
Latest SNSS insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| May 29, 2020 | Tina Gullotta | VP, Finance | Buy | $2K (6,000 @ $0.33) |
| Nov 29, 2019 | William P. Quinn | See Remarks | Buy | $2K (6,000 @ $0.37) |
| Jul 15, 2019 | Aisling Capital Partners IV LLC | 10% Owner | Buy | $1.5M (2,500,000 @ $0.60) |
| Jul 15, 2019 | Aisling Capital IV, LP | 10% Owner | Buy | $1.5M (2,500,000 @ $0.60) |
| Jul 15, 2019 | Steve Elms | 10% Owner | Buy | $1.5M (2,500,000 @ $0.60) |
| Jul 15, 2019 | Andrew N Schiff | 10% Owner | Buy | $1.5M (2,500,000 @ $0.60) |
| Jul 15, 2019 | Aisling Capital Partners IV, LP | 10% Owner | Buy | $1.5M (2,500,000 @ $0.60) |
| May 31, 2019 | William P. Quinn | See Remarks | Buy | $4K (6,000 @ $0.65) |
| Dec 10, 2018 | William P. Quinn | CFO,Sr.V.P. Finance, Corp.Dev. | Buy | $19K (40,000 @ $0.47) |
| Nov 6, 2017 | MPM Oncology Impact Management LP | 10% Owner | Buy | $45K (16,200 @ $2.77) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.